newsfilter
← Latest News
GlobeNewswire·

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in